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Secretory immunoglobulins have a critical role in defense of the gastrointestinal tract
and are known to act by preventing bacterial acquisition. A stringent murine model of
bacterial infection with Salmonella enterica Typhimurium was used to examine protection
mediated by oral passive immunization with human plasma-derived polyreactive IgA and
IgM antibodies (Abs) reconstituted as secretory-like immunoglobulins (SCIgA/M). This
reagent has been shown to trigger Salmonella agglutination and to limit the entry of
bacterium into intestinal Peyer’s patches via immune exclusion. We now demonstrate
that upon administration into ligated intestinal loops, SCIgA/M properly anchors in the
mucus and is protected from degradation to a better extent that IgA/M or IgG. Moreover,
prophylactic oral administration of SCIgA/M before intragastric infection of mice with a
virulent strain of S. enterica Typhimurium allows to protect infected animals, as reflected
by reduced colonization of both mucosal and systemic compartments, and conserved
integrity of intestinal tissues. In comparison with IgA/M or IgG administration, SCIgA/M
provided the highest degree of protection. Moreover, such protective efficacy is also
observed after therapeutic oral delivery of SCIgA/M. Either prophylactic or therapeutic
treatment with passively delivered SCIgA/M ensured survival of up to 50% of infected
mice, while untreated animals all died. Our findings unravel the potential of oral passive
immunization with plasma-derived polyreactive SCIgA/M Abs to fight gastrointestinal
infections.
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INTRODUCTION
Protection of mucosal surfaces against colonization and possible entry and invasion by microbes
is provided by a combination of constitutive, non-specific substances (mucus, lysozyme, and
defensins), and by specific cellular and molecular immune mechanisms including secretory
immunoglobulins (SIgs) (1, 2). In vivo, experimental and clinical resistance to infection can be
correlated with specific SIgA antibodies (Abs) serving as an immunological barrier at mucosal
surfaces (3, 4). They are produced by plasma cells in the basolateral part of the epithelium as dimeric
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molecules thanks to the presence of the J-chain. IgA are
transported across the epithelial barrier to the lumen by a specific
receptor that after cleavage remains linked to IgA and forms
the secretory component (SC). Association of dimeric IgA with
SC leads to SIgA generation. It is thought that agglutination,
immobilization, and neutralization of pathogens at mucosal
surfaces is facilitated by the multivalency of SIgA (5, 6) and the
presence of the SC (7). IgM offers a higher multivalency due to
its pentameric structure. Presence of the J-chain on IgM allows
also for the binding of SC and the generation of SIgM that are
released in the lumen similarly to SIgA. In patients with IgA-
deficient individuals, SIgM seem to serve as a surrogate of SIgA
(8) acting via a similar protective mechanism (9). However, its
assessment in vivo is missing.
The lack of effective vaccines against several infectious
agents, the emergence of new pathogenic strains, and problems
associated with antibiotic resistance, has led to a renewed
interest for passive immunization consisting of the exogenous
delivery of Abs as prophylactic and therapeutic agents. In
emergency situations that cannot wait for a vaccine to induce
protective immunity, direct intervention with biologically active
Ab molecules to the affected site represents the basis for topical
immunotherapy (10). Such a strategy relying on intravenous
injection of polyreactive IgG preparations (IVIg) has already
proven of high value in the case of severe systemic infections (11).
Because neutralization of microbes at mucosal surfaces is largely
mediated by SIgs, application along the gastrointestinal tract of
purified plasma-derived polyreactive IgA and IgM reconstituted
in SIgs (12) (SCIgA/M) deserves appraisal as an anti-pathogen
approach. Such preparations are derived from a pool of plasma
from thousands of donors and therefore contain both natural
polyreactive Abs known to interact with/control pathogenic
micro-organisms (13–15) and a repertoire of polyspecificities to
pathogens due to the natural history of infections that the donors
have been exposed to (16).
We have previously established that secretory-like IgA
and IgM (SCIgA/M) had the capacity to interact with
the enteropathogen Salmonella enterica Typhimurium and
promoted the formation of large aggregates of this particular
bacterium (17). Upon oral administration of immune complexes,
immune exclusion of the pathogen by SCIgA, and SCIgM
Abs resulted in reduced local infection in the gut and
diminished systemic dissemination (17). Fulfillment of these
essential prerequisites indicates that the exogenously delivered
Ab molecules exhibit the same functional features as locally
secreted endogenous Abs in the harsh gut environment.
Using a stringent experimental mouse model of S. enterica
Typhimurium (St) gut infection, we demonstrate that two
prophylactic oral administrations of SCIgA/M given 8 and 24 h
prior to infection with a lethal dose of St reduces tissue bacterial
load and mortality rate more efficiently than polymeric IgA/M or
IgG. In the more demanding therapeutic setting, one single dose
of SCIgA/M proved efficacious when delivered orally 1 or 8 h
Abbreviations: IgA/M, plasma-derived polyreactive IgA and IgM; SIgs, secretory
immunoglobulins; SC, secretory component; SCIgA/M, secretory-like IgA/M; St,
Salmonella enterica Typhimurium strain SL1344.
TABLE 1 | Oral infection of mice and passive administration of Abs.
PROPHYLACTIC SETTINGS
Bacterial infection assay
Mock-treated PBS 150 µl 2 × 107 St 100 µl
Ab-treated IgA/M/SCIgA/M/IgG 150 µl 2 × 107 St 100 µl
Mouse survival assay
Mock-treated PBS 150 µl 2 × 106 St 100 µl
Ab-treated IgA/M/SCIgA/M/IgG 150 µl 2 × 106 St 100 µl
THERAPEUTIC SETTINGS
Bacterial infection assay (treatment at + 1h only)
Mock-treated PBS 150 µl 2 × 107 St 100 µl
Ab-treated SCIgA/M 150 µl 2 × 107 St 100 µl
Bacterial infection assay (treatment at + 1h or + 8h)
Mock-treated PBS 150 µl 2 × 106 St 100 µl
Ab-treated SCIgA/M 150 µl 2 × 106 St 100 µl
Mouse survival assay
Mock-treated PBS 150 µl 2 × 106 St 100 µl
Ab-treated SCIgA/M 150 µl 2 × 106 St 100 µl
post-infection. Intrinsic stability and proper mucosal tethering
of SCIgA/M caused the difference in efficacy, and marks this
particular molecular form as that with optimal functionality for
oral immunotherapeutic intervention.
MATERIALS AND METHODS
Preparation of Human Plasma-Derived Abs
Purified human plasma-derived IgA/M and SCIgA/M were
prepared as published (17). Privigen (CSL Behring) was
used as the source of purified human plasma-derived IgG.
For visualization in vivo, Ab preparations were labeled with
indocyanin 5 (Cy5) fluorescent dye (Innova Biosciences Ltd).
Bacterial Strain and Culture Conditions
SL1344 [a streptomycin-resistant virulent strain of S. enterica
serovar Typhimurium (18); abbreviated St all along the
paper] was grown in Luria-Bertani broth containing 90µg/ml
streptomycin (Sigma-Aldrich) and used at mid-log growth
phase. Bacterial density was determined on the basis that 1
OD600nm corresponds to 9.5 × 10
8 CFU/ml. The inoculation
dose was verified by plating 10-fold serial dilutions on agar
plates.
Mice
Four week-old female BALB/c mice were obtained from
Charles River Laboratories (L’Arbresle, France) and used at
the age of 7–8 weeks. They were housed in the animal
facility of the Lausanne University State Hospital under
standard conditions. All experiments were approved by the
State Veterinary Office, Lausanne, Switzerland (permit number
VD2880) and performed in strict accordance to the guidelines of
the animal experimentation law (SR 455.163) of the Swiss Federal
Government.
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Ligated Intestinal Loops and Analysis of
Tissue Sections
Ligated intestinal loops were prepared (19), and 100 µl of a
solution containing 10 µg of Cy5-labeled SCIgA/M, IgA/M, or
IgG were delivered into the lumen. Mice were sacrificed 6 h
later (i.e., the maximal incubation time allowed by the State
Veterinary Office), the intestinal segment was removed, fixed in
500 µl of PBS-4% paraformaldehyde (Fluka) for 2 h at 4◦C, and
further processed as described (20). Tissue sections were labeled
with rabbit anti-mouse/human-MUC-2 IgG (1/50; Santa-Cruz
Biotechnology), followed by AlexaFluor647-labeled goat anti-
rabbit IgG (1/200; Life Technologies). Cell nuclei were stained
with DAPI. Laser scanning confocal microscopy images were
obtained using a Leica SP5 microscope in multi-track mode. Raw
images were analyzed and processed with Imaris 8 software to
generate 3D reconstitutions. One representative tissue section,
out of at least 2 independent experiments (several sections per
experiments), is displayed for each condition.
Ab Degradation Assay
The in vitro degradation assay was performed as described (21).
Detection of the reduced form of the heavy chain of each Ab
mixture was performed by immunoblotting using goat anti-
human alpha chain (1/1,000; Cappel), followed by HRP-labeled
rabbit anti-goat Ab (1/4,000; Sigma-Aldrich), or biotinylated
anti-human mu chain (1/1,000; KPL) or biotinylated anti-
human gamma chain (1/1,000; Sigma-Aldrich) sera, followed
by Extravidin-HRP (1/4,000; Sigma-Aldrich). The relative
quantification of intact heavy chains following degradation as
compared to the initial condition (0 h) has been performed
with Fusion FX7 software (Vilber Lourmat). Displayed blots are
examples of one particular experiment out of at least three that
have been compiled for the quantification analysis shown in the
Table 2.
For the in vivo degradation assay, 2 µg of unlabeled Abs
in 20 µl of PBS were injected in a mouse ligated intestinal
loop. After 6 h, mice were sacrificed, the loop’s tissue and
luminal content were collected and cut into small pieces. The
samples were incubated in 50mMHCl and CompleteTM protease
inhibitor (Roche Applied Science) for 16 h at 4◦C under gentle
shaking, then centrifuged for 10min at 2,350 × g. The clear
supernatant was collected and stored at −20◦C prior to use.
To ensure equivalent samples loading, the concentration of Abs
was determined through measurement by ELISA of stable anti-
human kappa chain signal (21). SDS-PAGE and immunoblot
analyses were performed as for the in vitro assay. The relative
quantification of degraded heavy chains signals as compared to
the total heavy chain signals has been performed with Fusion
FX7 software (Vilber Lourmat). Displayed blots are examples of
one particular experiment out of at least three that have been
compiled for the quantification analysis.
Oral Infection of Mice and Passive
Administration of Ab
Mice were orally infected with 2 × 107 (to assess bacterial entry
in prophylactic and therapeutic settings), 2 × 106 (to assess
bacterial entry in therapeutic settings), and 2× 106 (to determine
survival in prophylactic and therapeutic settings) St using a
round tip stainless steel needle (22) (Table 1). In the prophylactic
setting, 10mg of plasma-derived polyreactive SCIgA/M, IgA/M,
or IgG were orally administered 24 h and 8 h prior to bacteria
infection. In the therapeutic setting, 10mg of SCIgA/M were
orally administered 1 h or 8 h post-infection. Bacterial loads in
Peyer’s patches, mesenteric lymph nodes, spleen, and liver were
assessed 6 days post-infection by plating serial dilutions of tissue
lysates (22). Weight of mice and disease score (23) based on fur
ruﬄing, activity, posture, eye/nose discharge, and aspect of feces
were recorded on a daily basis. A compilation of data from three
(bacterial entry) or two (survival) independent experiments is
displayed.
Histological Analysis of Intestinal Tissues
At sacrifice, 1-cm sections of jejunum were collected, fixed in
paraformaldehyde, and cut into 5 parts before embedding in
paraffin. Seven micrometer sections were then prepared and
stained with hematoxylin and eosin to assess tissue integrity. At
least 10 tissue sections per animal were observed with an Axio
Imager Z1 microscope (Zeiss). One representative tissue section
is displayed for each condition.
Statistical Analysis
Statistical analysis was performed using Prism software
(GraphPad Software, Inc., La Jolla, CA). Bars represent median
of each experimental group. The unpaired, non-parametric
Mann–Whitney test, or the Kruskal–Wallis test, corrected with
Dunn’s test for multiple comparisons, was applied to compare
experimental groups with the “no Ab” condition, or SCIgA/M vs.
IgA/M. For survival experiments, the Kaplan-Meier curves were
calculated and a log-rank test was used to compare the survival
curves. ns, non-significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001;
∗∗∗∗p < 0.0001.
RESULTS
Plasma-Derived Polyreactive (SC)Ig/AM Is
Stable in the Intestinal Environment
The prerequisite for efficient humoral protection in the gut is
the ability of the Ab to interact with the mucus to limit its
elimination, and to resist to degradation by local proteases. To
assess bio-distribution, Cy5-labeled SCIgA/M, IgA/M, or IgG
Ab preparations were injected into a ligated intestinal loop and
incubated for 6 h prior to section preparation and staining for
MUC-2, a constituent of the mouse intestinal mucus. Analysis
by laser scanning confocal microscopy revealed numerous
SCIgA/M-corresponding bright red fluorescent spots embedded
within the MUC-2-positive areas overlying the epithelial cell
layer (Figure 1A). Less numerous and much weaker signals were
observed following administration of IgA/M or IgG in the ligated
intestinal loop. This indicates a reduced capacity of these two
Ab preparations to anchor in the mucus layer, consistent with
the essential role of SC in tethering polymeric Igs within mucus
Frontiers in Immunology | www.frontiersin.org 3 December 2018 | Volume 9 | Article 2970
Corthésy et al. Mucosal Protection by Secretory-Like IgA/M
TABLE 2 | Quantification of intact heavy chains in the in vitro degradation assay.
Alpha chain Mu chain Gamma chain
2 h 16 h 16 h 48 h 2 h 16 h
IgA/M 47.2 ± 9.2% 23.8 ± 11.9% 38.6 ± 18.1% 27.3 ± 11.1% n.d. n.d.
SCIgA/M 64.3 ± 24.8% 26.8 ± 9.8% 47.9 ± 10.7% 38.0 ± 10.5% n.d. n.d.
IgG n.d. n.d. n.d. n.d. 35.4 ± 0.5% 11.4 ± 1.5%
n.d., not done.
(7), and with the higher susceptibility to protease-mediated
degradation for non-secretory-like Igs in such an environment.
To address this possibility, the stability of the same set of
Abs was examined by testing their sensitivity to mouse intestinal
washes. After 2 h of incubation in intestinal washes, immunoblots
performed in reducing conditions indicated the presence of intact
alpha chain and some degradation products (Figure 1B and
Table 2). After overnight incubation, more intact alpha chain
signals were recovered for SCIgA/M preparations as compared
to IgA/M, consistent with the protective role ensured by SC (21).
The lesser sensitivity of mu chain to proteases in intestinal washes
(24) imposed to prolong digestion for up to 48 h; the presence
of SC in SCIgA/M reduced the conversion of the mu chain into
degraded species (Figure 1B and Table 2). In contrast, when IgG
was analyzed, the gamma chain was already largely degraded after
as few as 2 h, and almost no signal could be detected after 16 h.
Experiments performed in vivo in ligated intestinal loops showed
that the degradation of alpha and mu chains from SCIgA/M
and IgA/M was very partial, with slightly less degradation for
SCIgA/M. The proportions of degraded materials were 43.9 ±
12.3% of alpha chain and 25.4 ± 16.9% for mu chain (SCIgA/M)
as compared to 66.4± 20.0% for alpha chain and 53.6± 6.3% for
mu chain (IgA/M). Analysis of IgG resulted in the appearance of a
signal well below the expected molecular weight of native gamma
chain (Figure 1C), representing 57.5 ± 11.7% of gamma chain.
Due to the digestion time limited to 6 h for in vivo experiments
(see Materials and Methods), the presence of SC in SCIgA/M led
to a limited advantage in stability over IgA/M.
Together, these data demonstrate that after administration
in the intestinal environment, the SCIgA/M preparation, as
compared to IgA/M and IgG, combines the most optimal
anchoring and stability properties, two parameters that have been
associated with protective efficacy in the gut.
Protection Against Salmonella Infection Is
Best Mediated by Prophylactic Oral
Administration of SCIgA/M
To test the biological activity of SCIgA/M, as well as
the importance of SC in the preparation, prophylactic oral
administration of 10mg of SCIgA/M, IgA/M and IgG (as control)
was performed at 24 h and 8 h before intragastric inoculationwith
2 × 107 CFUs of St. Mice were kept for 6 days post-infection,
and the protective efficacy of the Abs was assessed at this time
by measuring the local intestinal and distant systemic bacterial
load. Prophylactic passive immunization with SCIgA/M turned
out to be the most potent at reducing the bacterial load in Peyer’s
patches, mesenteric lymph nodes, the spleen, and the liver of
infected mice (Figure 2A). Physiological symptoms of infection
including weight loss and disease score were best reduced
upon SCIgA/M administration (Figure 2B). IgA/M showed some
efficacy, as reflected by a significantly weaker disease score in
comparison with untreated-infected mice. A direct comparison
between SCIgA/M and IgA/M demonstrated a clear trend toward
a better protective effect of the former (p = 0.0040 for Peyer’s
patches, p = 0.0625 for mesenteric lymph nodes, p = 0.0625 for
the spleen, p = 0.8633 for the liver, p = 0.0019 for weight loss
and p = 0.1110 for disease scores). For all parameters assessed,
prophylactic treatment with IgG yielded no sign of improvement
of the animal’s health status at day 6 post-infection (Figure 2B).
St infection and its associated inflammatory response are
known to damage the intestinal epithelium, leading to additional
alteration of the gut function. Consistent with its capacity to
limit infection, prophylactic administration of SCIgA/M, and
to a lesser extent IgA/M, contributed to largely maintain the
architecture of the intestinal tissue 6 days post-infection. As
depicted in Figure 2C, histological analysis of intestinal tissue
showed preserved integrity of the epithelium, with only limited
shortening of the villi. In comparison, untreated-infected or
IgG treated-infected mice exhibited important tissue damages
as reflected by the massive destruction of the intestinal villus
structure (Figure 2C).
SCIgA/M Delays Disease Progression and
Improves Survival of Infected Mice
The correlation between the residual bacterial load and the
possible effect on the survival is important to validate protection.
To address this issue, the experimental focus was put on animals
having received prophylactically the best protective candidate
Ab, i.e., SCIgA/M at a dose of 10mg given orally 24 h and
8 h prior to infection with 2 × 106 St. In contrast to control
animals rapidly losing weight and reaching a high disease score
(Figures 3A,B), 5 out of 7 treated-infected mice showed a delay
in symptom progression. When looking at the survival rate, all
untreated mice died within 9 days post-infection (Figure 3C),
while 3 out of 7 survived after having received SCIgA/M. Overall,
prophylactic passive administration of the SCIgA/M preparation
has the ability to protect mice from subsequent oral infection
by lethal doses of St via multiple modes of action including
reduction of the bacterial load in tissues, maintenance of the
epithelium architecture, and delay of disease progression or
complete healing.
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FIGURE 1 | Location and stability of Ab preparations in the gastrointestinal tract. (A) Tissue sections prepared from mouse ligated intestinal loops 1.5 h
post-administration with either Cy5-labeled IgA/M, SCIgA/M, or IgG appearing in red. Sections were further stained with anti-MUC-2 antiserum and DAPI to detect
mucus and cell nuclei prior to analysis by laser scanning confocal microscopy. Examples of typical results of more than five samples are shown. L, Lumen.
Magnification, x 40 for all panels. (B) In vitro digestion patterns observed at three time points of IgA/M, SCIgA/M, and IgG incubated with intestinal washes, as assayed
by immunodetection of the respective heavy chain under reducing conditions. In (B,C), the position of the intact alpha, mu, and gamma chains is indicated by an
asterisk. (C) IgA/M, SCIgA/M, or IgG incubated for 6 h in a ligated intestinal loop were recovered as described in Materials and Methods, and analyzed as under (B).
Therapeutic Oral Administration of
SCIgA/M Protects Against Salmonella
Infection
The promising results obtained in the prophylactic setting
prompted us to assess the therapeutic protective efficacy of
SCIgA/M. When 2 × 107 St were used to orally infect
mice, administration of 10mg SCIgA/M 1 h later was able to
significantly reduce the bacterial load in mice recovered at
day 6 post-infection in both intestinal (Peyer’s patches and
mesenteric lymph nodes) and systemic (spleen and liver) tissues
(Figure 4A). Weight loss and disease score of treated mice were
less pronounced as compared to untreated animals (Figure 4B).
However, oral treatment performed 8 h post-infection did not
result in reduction of the infection (data not shown), most
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FIGURE 2 | Prophylactic administration of SCIgA/M preparation limits St entry and reduces symptoms. (A) Bacterial counts measured in Peyer’s patches (PPs),
mesenteric lymph nodes (MLNs), spleen, and liver 6 days post-infection by oral administration of 2 × 107 St into mice prophylactically treated with Ab preparations.
(B) Weight loss and disease score (see section Materials and Methods) determined at day 6 post-infection as a function of the Ab preparation administered
prophylactically. Each panel compiles the results of three independent experiments, conducted with 3 mice per group. (C) Histologic examination (hematoxylin and
eosin staining) of intestinal tissue sections obtained from infected mice 6 days post-administration with a single dose of either 2 × 107 St alone, or in the presence of
prophylactically applied Ab preparation. Typical patterns for “No Ab”/IgG (left) and IgA/M/SCIgA/M (right) representative of more than 10 sections. L, Lumen; V, Villus.
Magnification, x 20 for all images. ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
likely due to the amount of bacteria that had rapidly moved
across the epithelium prior to Ab treatment. We thus sought to
assess the protective efficacy of therapeutically applied SCIgA/M
with 10-fold less St, a dose that remains lethal between days
9 and 11 (see Figures 3C, 5A). Initial oral infection with
2 × 106 St followed by oral delivery of 10mg SCIgA/M
1 h later largely reduced the number of St 6 days post-
infection in either local or systemic compartments (Figure 4C).
Under these experimental conditions, delaying the time of
SCIgA/M administration to 8 h post-infection kept diminishing
the bacterial load significantly (Figure 4C). This translated into
improved status of the treated mice as compared to control
animals, resulting in less weight loss and a lower disease score
(Figure 4D).
The protective efficacy of a single dose of SCIgA/M assessed
at day 6 post-infection led us to hypothesize that therapeutic
application of these polyreactive Absmay have a positive effect on
the survival of mice post-infection. We therefore orally infected
mice with 2 × 106 St, and applied 10mg of SCIgA/M 8 h later;
the weight, the disease score and the survival of animals were
subsequently recorded for 20 days. In the untreated control
group, mice rapidly lost weight (Figure 5A) and demonstrated
signs of disease (Figure 5B), leading to the death of all mice
at day 11 post-infection (Figure 5C). In contrast, 4 out of 8
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FIGURE 3 | Prophylactic administration of SCIgA/M preparation promotes mouse survival. Time-dependent follow-up of mice infected with 2 × 106 St
post-prophylactic treatment (24 and 8 h) with oral delivery of the SCIgA/M preparation. Each depicted curve represents one individual mouse analyzed for weight loss
(A) and disease scores (B). Sacrifice (depicted by a
†
) of mice having lost ≥20% of their initial weight was done to comply with the Veterinary Office’s permit to
conduct animal experiments. Each panel compiles the results of 2 independent experiments. (C) Survival curves resulting from the compilation of all mice in either the
St alone group (red circles) or the prophylactically treated (SCIgA/M, St) group (green circles). **p < 0.01.
animals therapeutically treated with one oral administration of
10mg SCIgAM remained healthy for up to 20 days after infection.
Protected mice did not lose weight nor exhibit signs of disease
more pronounced than fur ruﬄing (Figure 5C). The other half
died from the infection, but displayed a delay in both weight loss
and the disease score’s evolution, as compared to control mice,
hence leading to prolonged survival.
Altogether, our data demonstrate that a single oral therapeutic
administration of polyreactive SCIgA/M at a time when St
infection is already ongoing entails the reduction of the intestinal
and systemic bacterial load and of the symptoms associated
with infection. Such a reduced invasiveness results in too little
colonization to cause fatal infection in 50% of infected mice,
comparing with 100% mortality in the absence of therapeutic
SCIgA/M.
DISCUSSION
For thousands of generations, mammals have exploited the
benefits of transferring colostrum- and breast milk-derived Abs
to newborns to ensure protection early in life via the large
repertoire associated with the mother’s previous exposure to
environmental pathogens (25–28). This evolution-related way
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FIGURE 4 | Therapeutic administration of SCIgA/M limits St entry and reduces symptoms (A) Bacterial counts measured 6 days post-infection with 2 × 107 St in
Peyer’s patches (PPs), mesenteric lymph nodes (MLNs), spleen, and liver from mice orally administered SCIgA/M 1h after oral infection. (B) Weight loss and disease
scores (see Materials and Methods) determined at day 6 post-infection of mice treated therapeutically with SCIgA/M as in (A). (C,D) Same experiments as in (A,B)
with infection performed with 2 × 106 St, followed by subsequent therapeutic oral administration of SCIgA/M 1 or 8 h after oral infection. Each panel compiles the
results of 3 independent experiments, conducted with 3 mice per group. ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
of providing protective Abs finds its current application in
systemic passive immunotherapy with polyclonal blood-based, or
monoclonal Abs, mostly IgGs (29–31). While efficacy has been
demonstrated in several human clinical trials at the systemic
level (32–36), examples of successful protection of mucosal
surfaces by local application of purified IgA (37, 38) or SIgA
(39, 40) are not plethora in the literature. Besides, such studies
were performed with monoclonal Abs only, while examples
with SIgM are missing. The rationale of our strategy, which
relies on the use of plasma-derived polyreactive SCIgA and
SCIgM delivered by the oral route, is based on the close
clonal relationship between mucosal and systemic plasma cells
(41). In addition, circulating IgA+ plasma cells originate from
mucosal immune inductive sites and disseminate systemically
(42), resulting in the production of polymeric IgA in the blood. In
support of this, we have observed that such antibody molecules
recovered from plasma samples bind to SC (12). This ensures
efficient recognition and control of enteropathogens both at their
site of entry and following systemic dissemination. These two
important features expected for mucosal passive immunization
are observed following prophylactic or therapeutic intervention
with SCIgA/M.
Exogenous mucosal delivery along the gastrointestinal tract
implies that the optimal molecular form of the Ab is
administered, i.e., SIgs. In support of their use for local passive
immunization, natural SIgA molecules display high in vitro
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FIGURE 5 | Therapeutic administration of SCIgA/M preparation promotes mouse survival Time-dependent follow-up of mice infected with 2 × 106 St prior to
therapeutic treatment carried out 8 h post-infection with a single dose of the SCIgA/M preparation. Each depicted curve represents one individual mouse analyzed for
weight loss (A) and disease scores (B). Sacrifice (depicted by a
†
) of mice having lost ≥20% of their initial weight was done to comply with the Veterinary Office’s
permit to conduct animal experiments. Each panel compiles the results of 2 independent experiments. (C) Survival curves resulting from the compilation of all mice in
either the St alone group (red circles) or the therapeutically treated (St, SCIgA/M) group (green circles). **p < 0.01.
stability upon exposure to intestinal washes rich in proteases
(21). Consistent with this, the current study shows that the lack
of SC reduces the stability of either plasma-derived IgA or IgM
in vivo and precludes proper anchoring within mucus. Such
biochemical features are crucial to ensure optimal functionality
of the SCIgA/M preparation toward enteropathogens, as this is
demonstrated inhere in prophylactic and therapeutic tratments
against Salmonella. In this context, control of the infection
is known to occur via immune exclusion which is based on
agglutination, enchained growth or both depending on the local
concentration of bacteria in the infected intestine (17, 43).
Interestingly, even though endogenous vaccine-induced high-
avidity IgA Abs seem highly potent at controlling Salmonella
infection (43), exogenous delivery of polyreactive SIgs displays
a promising level of protection. When assessed individually,
we found that purified SCIgA or SCIgM significantly decreased
the weight loss and disease score in infected animals, with
SCIgM showing the best performance (GB, unpublished
data). This suggests that polyreactive SIgM contributes to
mucosal protection, and provides a molecular explanation as
to why the Ab can compensate for SIgA in IgA-deficient
individuals (44).
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In contrast to maternal IgG possibly protected in the
colostrum/milk environment, passive delivery along the oral
route of this isotype in a purified form did not show any positive
impact on bacterial entry and dissemination. Based on our
results, the absence of protection after oral passive administration
of IgG can be attributed to the inadequate immunoglobulin
isotype and/or the instability of the Ab in the gut, further
arguing in favor of the use of polymeric and optimally secretory
Igs. A logical development of the study that already shows
efficacy after a single-dose in the therapeutic setting will involve
multiple experimental refinements requiring that different doses
of both the Ab and Salmonella be tested with various kinetics
of administration; we find it fair to say that such a demanding
development is beyond the scope of this proof-of-concept study.
Due to their intrinsic polyreactivity toward a broad range
of antigens, human plasma-derived polymeric Igs are somehow
“ready-to-be-used,” in contrast to humanized or chimeric specific
monoclonal Abs, which may need to be combined to cover a
sufficient diversity of recognition patterns. Another drawback,
selection pressure on a particular bacterial antigen by repeated
administration of a monoclonal Ab may favor mutation on one
hand, and give growth advantage to other co-infecting microbes
on another hand. While the technology to ensure production
of monoclonal IgG of defined specificity is well-established,
generation of polymeric IgA/IgM-secreting clones is not an
obvious task and may turn out to be pricy. In contrast, the
identification of modern biotechnology-based processes allows
the recovery of hundreds of gram amounts of biologically
active SIg molecules. For all these reasons, plasma-derived
IgA/M molecules thus appear a relevant alternative for future
human applications. Further, features including natural pattern
of glycosylation will not induce possible inhibitory human anti-
mouse Ab responses, in particular along the gastrointestinal tract
known to be a tolerance-prone environment. The absence of
overreaction toward non-self proteins such as biotechnology-
derived pharmaceuticals will thus not represent a problem with
orally administered SCIgA/M. Moreover, the lack of activation
of the complement cascade by SIgA (45, 46), restriction of both
SIgA and SIgM in the intestinal lumen, and local complement
regulatory proteins (47) should ensure absent or strongly reduced
inflammation in the gut. In addition, naturally existing plasma-
derived polyreactive Abs have a very low risk of technological
failure during the development process, and problems associated
with species matching for human application can be excluded.
Another obvious advantage lies in the intrinsic capability of
mucosally applied Ab preparations to neutralize the pathogen at a
very early stage of infection, or even prior to the initiation of the
infection. Data presented in this study bring valuable elements
as to the Ab isotypes, which need to be delivered to remain
active when facing a massive infection along the gastrointestinal
tract. Finally, although addition or recombinant SC necessary for
optimal function will have to be considered, its production via
CHO cells does not represent a bottleneck anymore.
The natural protection offered by passive immunization
has already provided the physicians with the opportunity to
envisage treatments against mucosal infectious agents with
Ab-enriched milk, serum, or egg yolk preparations (48). The
emergence of bacterial strains resistant to multiple antibiotics
and the major progresses made in Ab engineering give strong
arguments to thrive implementation of passive immunization.
The present study supports the notion that plasma-derived
polyreactive SCIgA and SCIgM may contribute to fulfill this
health need.
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